<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719741</url>
  </required_header>
  <id_info>
    <org_study_id>JHANES000001</org_study_id>
    <nct_id>NCT04719741</nct_id>
  </id_info>
  <brief_title>Drug and Dose Adjustment in Preventing Postoperative Nausea and Vomiting</brief_title>
  <official_title>Drug and Dosage Adjustment in Preventing Postoperative Nausea and Vomiting in Adult Patients Undergoing Elective Surgery Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jordan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to evaluate the effectiveness of different regimens of prophylactic Ondansetron,&#xD;
      Dexamethasone, or both, on the incidence and severity of post-operative nausea and vomiting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to one of four arms: Ondansetron (4O-PE: 4 mg Ondansetron&#xD;
      pre-emergence, 8O-PE: 8 mg Ondansetron pre-emergence, 4O-PI: 4 mg Ondansetron pre-incision,&#xD;
      8O-PI: 8 mg Ondansetron pre-incision), Dexamethasone (4D-PE: 4 mg Dexamethasone&#xD;
      pre-emergence, 8D-PE: 8 mg Dexamethasone pre-emergence, or 4D-PI: 4 mg Dexamethasone&#xD;
      pre-incision, or 8D-PI: 8 mg Dexamethasone pre-incision), Combination Therapy group&#xD;
      (4O-PI+8D-PI: 4 mg Ondansetron pre-incision + 8 mg Dexamethasone pre-incision, 4O-PI+8D-PE: 4&#xD;
      mg Ondansetron pre-incision + 8 mg Dexamethasone pre-emergence, 4 O-PE+8D-PI: 4 mg&#xD;
      Ondansetron pre-emergence + 8 mg Dexamethasone pre-induction, 4 O-PE+8D-PE: 4 mg Ondansetron&#xD;
      pre-emergence + 8 mg Dexamethasone pre-emergence), and Placebo group 2 ml Saline 0.9%.&#xD;
      Primary outcome will be the incidence of PONV in the PACU prior to discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2021</start_date>
  <completion_date type="Anticipated">May 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Presence of postoperative nausea and/or vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Follow if the patient complained about postoperative nausea and/or vomiting in terms of use of antiemetic drugs</description>
  </primary_outcome>
  <number_of_groups>13</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>O-4PI</arm_group_label>
    <description>4 mg Ondansetron given Pre-Induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O-8PI</arm_group_label>
    <description>8 mg Ondansetron given Pre-Induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O-4PE</arm_group_label>
    <description>4 mg Ondansetron given Pre-Emergence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O-8PE</arm_group_label>
    <description>8 mg Ondansetron given Pre-Emergence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-4PI</arm_group_label>
    <description>4 mg Dexamethasone given Pre-Induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-8PI</arm_group_label>
    <description>8 mg Dexamethasone given Pre-Induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-4PE</arm_group_label>
    <description>4 mg Dexamethasone given Pre-Emergence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-8PE</arm_group_label>
    <description>8 mg Dexamethasone given Pre-Emergence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O-4PI+D-8PI</arm_group_label>
    <description>4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O-4PI+D-8PE</arm_group_label>
    <description>4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-emergence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O-4PE+D-8PI</arm_group_label>
    <description>4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O-4PE+D-8PE</arm_group_label>
    <description>4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-emergence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <description>2 ml Saline 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parallel Assignment</intervention_name>
    <description>Prospective, Triple blinded, randomized, controlled trial</description>
    <arm_group_label>D-4PE</arm_group_label>
    <arm_group_label>D-4PI</arm_group_label>
    <arm_group_label>D-8PE</arm_group_label>
    <arm_group_label>D-8PI</arm_group_label>
    <arm_group_label>O-4PE</arm_group_label>
    <arm_group_label>O-4PE+D-8PE</arm_group_label>
    <arm_group_label>O-4PE+D-8PI</arm_group_label>
    <arm_group_label>O-4PI</arm_group_label>
    <arm_group_label>O-4PI+D-8PE</arm_group_label>
    <arm_group_label>O-4PI+D-8PI</arm_group_label>
    <arm_group_label>O-8PE</arm_group_label>
    <arm_group_label>O-8PI</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients undergoing elective surgery under general anesthesia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA grade I and II&#xD;
&#xD;
          -  Aged 18-70 years&#xD;
&#xD;
          -  Patients scheduled for elective surgery under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All patients who received antiemetics or cortisone within 48 hr before surgery&#xD;
&#xD;
          -  Pregnant, breast feeding ladies&#xD;
&#xD;
          -  Any patient with BMI (Body Mass Index) &gt; 34 kg/mÂ²&#xD;
&#xD;
          -  Patient with gastrointestinal, hepatic, renal, mental or psychiatric illnesses were&#xD;
             also excluded from the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbdulRhman MA Ibnouf, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Anaesthesia Department, Jordan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbdulRhman MA Ibnouf, MBBS</last_name>
    <phone>+962786468830</phone>
    <email>ibnouf@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jordan Hospital</name>
      <address>
        <city>Amman</city>
        <zip>11152</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AbdulRhman MA Ibnouf, MBBS</last_name>
      <phone>+962786468830</phone>
      <email>ibnouf@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jordan Hospital</investigator_affiliation>
    <investigator_full_name>AbdulRhman MA. M. Ibnouf</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>postoperative</keyword>
  <keyword>dose adjustment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

